Valeant (VRX) PT Cut to $106 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
Valeant Pharma (VRX) Pares Earlier Decline
March 1, 2016 2:28 PM ESTValeant Pharma (NYSE: VRX) pared earlier declines to trade lower by only 1.3%.
RBC Capital Downgrades Valeant Pharmaceuticals (VRX) to Sector Perform
March 1, 2016 7:36 AM ESTRBC Capital downgraded Valeant Pharmaceuticals (NYSE: VRX) from Outperform to Sector Perform with a price target of $85.00 (from $194.00).
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $65.80 yesterday.
... MoreSEC Investigation Extends Valeant Pharma's (VRX) Road to Confidence - BMO
March 1, 2016 7:18 AM ESTBMO Capital analyst, Alex Arfaei, takes a stab at valuing Valeant (NYSE: VRX) while acknowledging the limited visibility into the financial impact of the investigation. No change to Market Perform rating.
The SEC investigation and the form 10-K filing delay increase concerns about the integrity of Valeants financial reporting. It is very difficult to predict the potential range of outcomes of this... More
Deutsche Bank Suspends Coverage on Valeant Pharma (VRX)
March 1, 2016 6:49 AM ESTDeutsche Bank suspended its rating on Valeant Pharma (NYSE: VRX). The bank's prior rating was 'Hold'.
Analyst Gregg Gilbert said, "Based on Valeants plans to restate prior results, the delay in filing its 10-K, the removal of prior 16 guidance, and an ongoing Board... More
Clinton campaign says TV spot shows commitment to fight predatory drug pricing
March 1, 2016 5:02 AM ESTWASHINGTON (Reuters) - A television advertisement set to air on Tuesday from the presidential campaign of Hillary Clinton underscores the Democratic front-runner's willingness to take on predatory drug pricing, according to a campaign statement.
The ad, set to run in nominating contests following Super Tuesday voting and titled... More
Valeant Pharma (VRX) Provides Statement on SEC Investigation
February 29, 2016 4:41 PM ESTValeant Pharma (NYSE: VRX) said:
"In response to media inquiries, Valeant confirmed that it has several ongoing investigations, including investigations by the US Attorneys Offices for Massachusetts and the Southern District of New York, the SEC, and Congress. With respect to the SEC... More
Valeant Pharma (VRX) Says It's Under Investigation by SEC
February 29, 2016 3:36 PM EST(Updated - February 29, 2016 3:38 PM EST)
Valeant Pharma (NYSE: VRX) said it's under investigation by the SEC, according to Bloomberg, citing spokesperson Laurie Little. The probe is said to be separate from the Salix investigation.
"In response to media inquiries, Valeant confirmed that it... More
